📊 ALHC Key Takeaways
Is Alignment Healthcare, Inc. (ALHC) a Good Investment?
Alignment Healthcare demonstrates strong revenue growth of 46.1% YoY and positive free cash flow generation of $113.1M, indicating operational traction in the healthcare services sector. However, near-zero net profitability (-0.0% margin), minimal operating margin (0.4%), and negative ROE/ROA suggest the company is not yet converting strong top-line growth into sustainable bottom-line earnings, requiring proof of margin expansion.
Alignment Healthcare is showing strong fundamental momentum, with revenue up 46.1% year over year and the business moving close to break-even while also producing positive operating cash flow and free cash flow. The balance sheet has meaningful cash support and acceptable liquidity, but leverage is still elevated and margins remain extremely thin, so the growth story still needs proof of durable profitability.
Why Buy Alignment Healthcare, Inc. Stock? ALHC Key Strengths
- Strong revenue growth of 46.1% YoY demonstrates significant market demand and operational scaling
- Solid free cash flow of $113.1M with 2.9% FCF margin indicates underlying business can generate cash despite low net income
- Healthy liquidity position with current ratio of 1.71x and substantial cash reserves of $575.8M provides financial flexibility
- Positive operating cash flow of $139.9M exceeds modest capital expenditure of $26.8M, showing efficient capital deployment
- Revenue growth is exceptionally strong at 46.1% year over year, indicating expanding scale
- Operating cash flow of $139.93M and free cash flow of $113.15M suggest improving cash-generating quality
- Cash and equivalents of $575.82M with a 1.71x current ratio provide a solid liquidity cushion
ALHC Stock Risks: Alignment Healthcare, Inc. Investment Risks
- Near-zero net profitability (-0.0% net margin) despite 46.1% revenue growth indicates significant operating inefficiencies or high cost structure not scaling proportionally
- Negative return metrics (ROE -0.4%, ROA -0.1%) demonstrate shareholder value is being destroyed rather than created despite growth
- High leverage with debt/equity ratio of 1.80x combined with minimal profitability reduces margin of safety and limits financial flexibility
- Substantial insider activity with 36 Form 4 filings in 90 days warrants scrutiny for potential insider selling or unusual transactions
- Operating margin of only 0.4% on $3.9B revenue leaves minimal cushion for operational disruptions in highly regulated healthcare sector
- Operating margin of 0.4% and slightly negative net income show profitability is not yet firmly established
- Debt-to-equity of 1.80x and interest coverage of 2.7x indicate leverage is still a real constraint
- Growth quality must be monitored to ensure expansion is not coming with persistent low-margin economics
Key Metrics to Watch
- Operating margin expansion and path to sustainable profitability - critical test of business model viability
- Year-over-year revenue growth sustainability - whether 46.1% growth can be maintained as company scales
- Free cash flow to net income conversion - assess whether company can translate cash generation into actual earnings
- Debt service coverage and leverage ratios - monitor financial stability given 1.80x debt/equity ratio
- Insider transaction patterns and volumes - continue tracking Form 4 filings for signs of confidence or concern from management
- Operating and net margin progression
- Debt reduction and interest coverage improvement
Alignment Healthcare, Inc. (ALHC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 2.9% FCF margin may limit capital allocation flexibility.
ALHC Profit Margin, ROE & Profitability Analysis
ALHC vs Healthcare Sector: How Alignment Healthcare, Inc. Compares
How Alignment Healthcare, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alignment Healthcare, Inc. Stock Overvalued? ALHC Valuation Analysis 2026
Based on fundamental analysis, Alignment Healthcare, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alignment Healthcare, Inc. Balance Sheet: ALHC Debt, Cash & Liquidity
ALHC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alignment Healthcare, Inc.'s revenue has grown significantly by 54% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.79 indicates the company is currently unprofitable.
ALHC Revenue Growth, EPS Growth & YoY Performance
ALHC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $692.4M | $3.7M | $0.02 |
| Q2 2025 | $681.3M | $6.6M | $0.03 |
| Q1 2025 | $628.6M | -$9.1M | $-0.05 |
| Q3 2024 | $456.7M | -$26.4M | $-0.14 |
| Q2 2024 | $462.4M | -$24.0M | $-0.13 |
| Q1 2024 | $439.2M | -$37.3M | $-0.20 |
| Q3 2023 | $360.0M | -$35.0M | $-0.19 |
| Q2 2023 | $366.2M | -$11.6M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Alignment Healthcare, Inc. Dividends, Buybacks & Capital Allocation
ALHC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alignment Healthcare, Inc. (CIK: 0001832466)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 15, 2026 | 4 | xslF345X06/wk-form4_1776300091.xml | View → |
| Apr 13, 2026 | 4 | xslF345X06/wk-form4_1776119869.xml | View → |
| Apr 8, 2026 | 4 | xslF345X06/wk-form4_1775685070.xml | View → |
| Apr 8, 2026 | 4 | xslF345X06/wk-form4_1775684887.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/wk-form4_1775081790.xml | View → |
❓ Frequently Asked Questions about ALHC
What is the AI rating for ALHC?
Alignment Healthcare, Inc. (ALHC) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALHC's key strengths?
Claude: Strong revenue growth of 46.1% YoY demonstrates significant market demand and operational scaling. Solid free cash flow of $113.1M with 2.9% FCF margin indicates underlying business can generate cash despite low net income. ChatGPT: Revenue growth is exceptionally strong at 46.1% year over year, indicating expanding scale. Operating cash flow of $139.93M and free cash flow of $113.15M suggest improving cash-generating quality.
What are the risks of investing in ALHC?
Claude: Near-zero net profitability (-0.0% net margin) despite 46.1% revenue growth indicates significant operating inefficiencies or high cost structure not scaling proportionally. Negative return metrics (ROE -0.4%, ROA -0.1%) demonstrate shareholder value is being destroyed rather than created despite growth. ChatGPT: Operating margin of 0.4% and slightly negative net income show profitability is not yet firmly established. Debt-to-equity of 1.80x and interest coverage of 2.7x indicate leverage is still a real constraint.
What is ALHC's revenue and growth?
Alignment Healthcare, Inc. reported revenue of $3.9B.
Does ALHC pay dividends?
Alignment Healthcare, Inc. does not currently pay dividends.
Where can I find ALHC SEC filings?
Official SEC filings for Alignment Healthcare, Inc. (CIK: 0001832466) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALHC's EPS?
Alignment Healthcare, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALHC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Alignment Healthcare, Inc. has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALHC stock overvalued or undervalued?
Valuation metrics for ALHC: ROE of -0.4% (sector avg: 15%), net margin of 0.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALHC stock in 2026?
Our dual AI analysis gives Alignment Healthcare, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALHC's free cash flow?
Alignment Healthcare, Inc.'s operating cash flow is $139.9M, with capital expenditures of $26.8M. FCF margin is 2.9%.
How does ALHC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 0.0% (avg: 12%), ROE -0.4% (avg: 15%), current ratio 1.71 (avg: 2).
Is Alignment Healthcare, Inc. carrying too much debt?
ALHC has a debt-to-equity ratio of 1.80x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.71 suggests adequate short-term liquidity.